PDF(Pubmed)
Abstract：
Intravenous (IV) vitamin C improves organ function and reduces inflammation in sepsis, an inflammatory state like the post-hematopoietic stem cell transplant (HCT) milieu. The safety and efficacy of parenteral vitamin C after allogeneic HCT were evaluated in a phase I/II trial. Clinical outcomes were compared with a propensity score - matched historical control.
UNASSIGNED: Patients with advanced hematologic malignancies received IV vitamin C, 50mg/kg/d, divided into 3 doses given on days 1-14 after HCT, followed by 500 mg bid oral from day 15 until 6 months post-SCT.
UNASSIGNED: 55 patients received IV vitamin C. All patients were deficient in vitamin C at day 0. Vitamin C recipients had lower non-relapse mortality (NRM) (p = 0.07) and improved survival compared to historical controls (p=0.06), with no attributable grade 3 and 4 toxicities. Vitamin C recipients had similar relapse rate and acute graft versus host disease (GVHD) (p=0.35), but lower severe chronic GVHD (p=0.35). Patients with myeloid malignancies had improved survival (p=0.02) and NRM (p=0.009), as well as chronic GVHD, with similar relapse rates compared to controls.
UNASSIGNED: In patients undergoing allogeneic HCT the administration of IV vitamin C is safe and reduces non-relapse mortality and chronic GVHD improving overall survival.
UNASSIGNED: Patients with advanced hematologic malignancies received IV vitamin C, 50mg/kg/d, divided into 3 doses given on days 1-14 after HCT, followed by 500 mg bid oral from day 15 until 6 months post-SCT.
UNASSIGNED: 55 patients received IV vitamin C. All patients were deficient in vitamin C at day 0. Vitamin C recipients had lower non-relapse mortality (NRM) (p = 0.07) and improved survival compared to historical controls (p=0.06), with no attributable grade 3 and 4 toxicities. Vitamin C recipients had similar relapse rate and acute graft versus host disease (GVHD) (p=0.35), but lower severe chronic GVHD (p=0.35). Patients with myeloid malignancies had improved survival (p=0.02) and NRM (p=0.009), as well as chronic GVHD, with similar relapse rates compared to controls.
UNASSIGNED: In patients undergoing allogeneic HCT the administration of IV vitamin C is safe and reduces non-relapse mortality and chronic GVHD improving overall survival.
摘要：
静脉（IV）维生素C可改善器官功能并减少败血症的炎症，如造血干细胞移植（HCT）后环境的炎症状态。在I/II期试验中评估了同种异体HCT后肠胃外维生素C的安全性和有效性。将临床结果与倾向评分匹配的历史对照进行比较。方法：晚期恶性血液病患者接受静脉注射维生素C，50mg/kg/d，在HCT后第1-14天分为3剂，然后从SCT后第15天至6个月口服500mgbid。结果55例患者接受IV维生素C。所有患者在第0天缺乏维生素C。与历史对照相比，维生素C受体的非复发死亡率（NRM）较低（p=0.07），生存率提高（p=0.06）。没有可归因的3级和4级毒性。维生素C受体有相似的复发率和急性移植物抗宿主病（GVHD）（p=0.35），但较低的严重慢性GVHD（p=0.35）。骨髓性恶性肿瘤患者的生存率（p=0.02）和NRM（p=0.009）均得到改善，以及慢性GVHD，与对照组相比，复发率相似。结论：在接受同种异体HCT的患者中，静脉注射维生素C是安全的，可降低非复发死亡率和慢性GVHD，从而改善总体生存率。
